

Ranjani Somayaji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8967687/publications.pdf>

Version: 2024-02-01

84
papers

5,294
citations

257357

24
h-index

95218

68
g-index

85
all docs

85
docs citations

85
times ranked

8802
citing authors

#	ARTICLE	IF	CITATIONS
1	Mathematical model of the cost-effectiveness of the BioFire FilmArray Blood Culture Identification (BCID) Panel molecular rapid diagnostic test compared with conventional methods for identification of <i>Escherichia coli</i> bloodstream infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 507-516.	1.3	9
2	A longitudinal population-based study of predictors of mortality from bloodstream infections in Calgary, Alberta, Canada. <i>Future Microbiology</i> , 2022, 17, 17-25.	1.0	0
3	Just breathe: a review of sex and gender in chronic lung disease. <i>European Respiratory Review</i> , 2022, 31, 210111.	3.0	32
4	Human papillomavirus (HPV) and cervical dysplasia in adult female cystic fibrosis (CF) lung transplant recipients. <i>Thorax</i> , 2022, 77, 625-627.	2.7	7
5	Antimicrobial Stewardship in Wound Care. <i>Advances in Skin and Wound Care</i> , 2022, 35, 405-407.	0.5	0
6	Lymphocutaneous spread of <i>Mycobacterium elephantis</i> in an immunocompetent individual: A case report. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110349.	0.2	0
7	Forgoing transesophageal echocardiogram in selected patients with complicated <i>Staphylococcus aureus</i> bacteremia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 623-631.	1.3	4
8	Rifampin-resistant/multidrug-resistant Tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting. <i>PLoS ONE</i> , 2021, 16, e0246993.	1.1	2
9	Azithromycin and the microbiota of cystic fibrosis sputum. <i>BMC Microbiology</i> , 2021, 21, 96.	1.3	14
10	Glycated Albumin Triggers an Inflammatory Response in the Human Airway Epithelium and Causes an Increase in Ciliary Beat Frequency. <i>Frontiers in Physiology</i> , 2021, 12, 653177.	1.3	4
11	Characteristics and Outcomes of Children With Cystic Fibrosis Hospitalized With Cirrhosis in the United States. <i>American Journal of Gastroenterology</i> , 2021, 116, 1734-1737.	0.2	4
12	Comparative Analysis of Molecular and Serologic Testing for Primary Syphilis: A Population-Based Cohort Study. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 579660.	1.8	5
13	Platelets in Bronchiectasis: Player or Spectator?. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1287-1288.	1.5	1
14	Age and sex-specific incidence rates of group A streptococcal pharyngitis between 2010 and 2018: a population-based study. <i>Future Microbiology</i> , 2021, 16, 1053-1062.	1.0	3
15	Comparative clinical characteristics and outcomes of patients with community acquired bacteremia caused by <i>Escherichia coli</i> , <i>Burkholderia pseudomallei</i> and <i>Staphylococcus aureus</i> : A prospective observational study (Ubon-sepsis). <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009704.	1.3	7
16	A Comprehensive Review of the Pathogenesis, Diagnosis, and Management of Diabetic Foot Infections. <i>Advances in Skin and Wound Care</i> , 2021, 34, 574-581.	0.5	15
17	Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 392.	0.8	8
18	Healthcare workers' perception of gender and work roles during the COVID-19 pandemic: a mixed-methods study. <i>BMJ Open</i> , 2021, 11, e056434.	0.8	11

#	ARTICLE	IF	CITATIONS
19	Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 430-437.	2.5	50
20	Clinical Outcomes Associated with <i>Burkholderia cepacia</i> Complex Infection in Patients with Cystic Fibrosis. Annals of the American Thoracic Society, 2020, 17, 1542-1548.	1.5	19
21	Lack of nosocomial transmission to exposed inpatients and coworkers in an investigation of five SARS-CoV-2 infected healthcare workers. Infection Control and Hospital Epidemiology, 2020, 42, 1-2.	1.0	2
22	Cystic fibrosis – Ten promising therapeutic approaches in the current era of care. Expert Opinion on Investigational Drugs, 2020, 29, 1107-1124.	1.9	8
23	Exploring Tropical Infections: A Focus on Scrub Typhus. Advances in Skin and Wound Care, 2020, 33, 550-552.	0.5	0
24	Sputum microbiota in adults with CF associates with response to inhaled tobramycin. Thorax, 2020, 75, 1058-1064.	2.7	23
25	Cystic Fibrosis Patients Infected With Epidemic <i>Pseudomonas aeruginosa</i> Strains Have Unique Microbial Communities. Frontiers in Cellular and Infection Microbiology, 2020, 10, 173.	1.8	8
26	Clinical characteristics and outcomes for paediatric patients admitted with congenital or acquired syphilis: a population-based cohort study. Sexually Transmitted Infections, 2020, 96, 582-586.	0.8	2
27	Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respiratory Medicine, the, 2020, 8, 585-596.	5.2	1,049
28	Exploring Tropical Infections: A Focus on Cutaneous Larva Migrans. Advances in Skin and Wound Care, 2020, 33, 356-359.	0.5	7
29	Incidence, treatment, and outcomes of isoniazid mono-resistant <i>Mycobacterium tuberculosis</i> infections in Alberta, Canada from 2007-2017. PLoS ONE, 2020, 15, e0229691.	1.1	11
30	Epidemiology of cardiac implantable electronic device infections in the United States: A population-based cohort study. Heart Rhythm, 2020, 17, 1125-1131.	0.3	24
31	Underweight Patients With Cystic Fibrosis Have Acceptable Survival Following Lung Transplantation. Chest, 2020, 157, 898-906.	0.4	35
32	Epidemiology of <i>E. coli</i> in Cystic Fibrosis Airways Demonstrates the Capacity for Persistent Infection but Not Patient-Patient Transmission. Frontiers in Microbiology, 2020, 11, 475.	1.5	6
33	Canadian Burden of Skin Disease From 1990 to 2017: Results From the Global Burden of Disease 2017 Study. Journal of Cutaneous Medicine and Surgery, 2020, 24, 161-173.	0.6	15
34	Update on the adverse effects of antimicrobial therapies in community practice. Canadian Family Physician, 2020, 66, 651-659.	0.1	15
35	Epidemiology and Outcome Determinants of <i>Staphylococcus aureus</i> Bacteremia Revisited: A Population-Based Study. Infection, 2019, 47, 961-971.	2.3	26
36	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	13.7	161

#	ARTICLE	IF	CITATIONS
37	LUNG TRANSPLANT CENTER-SPECIFIC PATIENT MIX AND WAITLIST OUTCOMES FOR CANDIDATES WITH CYSTIC FIBROSIS IN THE UNITED STATES. Chest, 2019, 156, A142-A143.	0.4	0
38	Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. Journal of Cystic Fibrosis, 2019, 18, 236-243.	0.3	84
39	Infectious diseases consultation improves key performance metrics in the management of Staphylococcus aureus bacteremia: A multicentre cohort study. Jammi, 2019, 4, 24-32.	0.3	2
40	The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome. Journal of Cystic Fibrosis, 2019, 18, 829-837.	0.3	21
41	Cytomegalovirus: an unrecognised potential contributor to cystic fibrosis disease progression?. European Respiratory Journal, 2019, 53, 1801727.	3.1	2
42	Incidence, impact and natural history of Klebsiella species infections in cystic fibrosis: A longitudinal single center study. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 148-154.	0.2	0
43	Timing of device reimplantation and reinfection rates following cardiac implantable electronic device infection: a systematic review and meta-analysis. BMJ Open, 2019, 9, e029537.	0.8	11
44	Early management of sepsis in medical patients in rural Thailand: a single-center prospective observational study. Journal of Intensive Care, 2019, 7, 55.	1.3	11
45	Scratching the Surface: A Review of Dermatitis. Advances in Skin and Wound Care, 2019, 32, 542-549.	0.5	6
46	Diagnosis and Management of Cutaneous Tinea Infections. Advances in Skin and Wound Care, 2019, 32, 350-357.	0.5	9
47	Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respiratory Medicine, the, 2019, 7, 69-89.	5.2	326
48	Infrared Skin Thermometry: Validating and Comparing Techniques to Detect Periwound Skin Infection. Advances in Skin and Wound Care, 2018, 31, 607-611.	0.5	12
49	Understanding the Role of Staphylococcus aureus in Non-Cystic Fibrosis Bronchiectasis: Where Are We Now?. Annals of the American Thoracic Society, 2018, 15, 310-311.	1.5	5
50	Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study. Clinical Infectious Diseases, 2018, 67, 1089-1095.	2.9	47
51	Epidemiology and trends of cryptococcosis in the United States from 2000 to 2007: A population-based study. International Journal of STD and AIDS, 2018, 29, 453-460.	0.5	23
52	Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls. Paediatric Drugs, 2018, 20, 1-7.	1.3	3
53	1481. Clinical Outcomes of Escherichia coli Infections in Cystic Fibrosis (CF) Patients. Open Forum Infectious Diseases, 2018, 5, S458-S458.	0.4	1
54	Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 1061-1082.	4.9	221

#	ARTICLE	IF	CITATIONS
55	Clinical epidemiology and outcomes of community acquired infection and sepsis among hospitalized patients in a resource limited setting in Northeast Thailand: A prospective observational study (Ubon-sepsis). PLoS ONE, 2018, 13, e0204509.	1.1	30
56	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infectious Diseases, The, 2018, 18, 1191-1210.	4.6	1,084
57	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infectious Diseases, The, 2018, 18, 1211-1228.	4.6	862
58	Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis. Clinical Microbiology Reviews, 2018, 31, .	5.7	179
59	Benefits of set length antibiotic treatment for pulmonary exacerbations. Lancet Respiratory Medicine,the, 2018, 6, 575-577.	5.2	0
60	Epidemiology and natural history of <i>Pseudomonas aeruginosa</i> airway infections in non-cystic fibrosis bronchiectasis. ERJ Open Research, 2018, 4, 00162-2017.	1.1	14
61	Sputum microbiota is predictive of long-term clinical outcomes in young adults with cystic fibrosis. Thorax, 2018, 73, 1016-1025.	2.7	65
62	A Scoping Review of the Use of Silver-impregnated Dressings for the Treatment of Chronic Wounds. Ostomy - Wound Management, 2018, 64, 14-31.	0.8	6
63	Effect of freezing sputum on Pseudomonas aeruginosa population heterogeneity. Journal of Cystic Fibrosis, 2017, 16, 353-357.	0.3	4
64	Prosthetic joint and implant contamination caused by <i>Ralstonia pickettii</i>: a report of three cases. Sicot-j, 2017, 3, 32.	0.8	3
65	Clinical Outcomes Associated with <i>Achromobacter</i> Species Infection in Patients with Cystic Fibrosis. Annals of the American Thoracic Society, 2017, 14, 1412-1418.	1.5	35
66	The effects of inhaled aztreonam on the cystic fibrosis lung microbiome. Microbiome, 2017, 5, 51.	4.9	53
67	Common clinical features of CF (respiratory disease and exocrine pancreatic insufficiency). Presse Medicale, 2017, 46, e109-e124.	0.8	10
68	Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study. Clinical Infectious Diseases, 2017, 64, 1760-1767.	2.9	44
69	Long-term clinical outcomes of â€˜Prairie Epidemic Strainâ€™ <i>Pseudomonas aeruginosa</i> infection in adults with cystic fibrosis. Thorax, 2017, 72, 333-339.	2.7	17
70	Examining sociodemographic risk factors for <i>Chlamydia trachomatis</i> infection: a population-based cohort study. Future Microbiology, 2017, 12, 1363-1370.	1.0	1
71	Comparative Analysis of Incidence and Outcomes of Acute Hepatitis A (HAV) and B Virus Infections (HBV) in Children Aged â‰¥ 20 years in the United States (US). Open Forum Infectious Diseases, 2017, 4, S245-S245.	0.4	0
72	The impact of team based interprofessional comprehensive assessments on the diagnosis and management of diabetic foot ulcers: A retrospective cohort study. PLoS ONE, 2017, 12, e0185251.	1.1	19

#	ARTICLE	IF	CITATIONS
73	Human infections due to <i>Staphylococcus pseudintermedius</i> , an emerging zoonosis of canine origin: report of 24 cases. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 471-476.	0.8	155
74	Exploring <i>Staphylococcus pseudintermedius</i> : an emerging zoonotic pathogen?. <i>Future Microbiology</i> , 2016, 11, 1371-1374.	1.0	28
75	Pilonidal Sinus Disease: 10 Steps to Optimize Care. <i>Advances in Skin and Wound Care</i> , 2016, 29, 469-478.	0.5	32
76	Epidemic <i>Pseudomonas aeruginosa</i> infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 392-399.	0.3	20
77	Clinical Implications of Group A <i>Streptococcus</i> (GAS) Infections in Adults With Cystic Fibrosis (CF). <i>Chest</i> , 2015, 148, 122A.	0.4	0
78	Clinical implications and characterization of Group A <i>Streptococcus</i> infections in adults with cystic fibrosis. <i>BMC Pulmonary Medicine</i> , 2015, 15, 161.	0.8	10
79	Cognitive load imposed by knobology may adversely affect learners' perception of utility in using ultrasonography to learn physical examination skills, but not anatomy. <i>Anatomical Sciences Education</i> , 2015, 8, 197-204.	2.5	42
80	Optimizing the Moisture Management Tightrope with Wound Bed Preparation 2015®. <i>Advances in Skin and Wound Care</i> , 2015, 28, 466-476.	0.5	40
81	Reduction in <i>Pseudomonas aeruginosa</i> sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response. <i>BMC Infectious Diseases</i> , 2015, 15, 145.	1.3	46
82	Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of <i>Pseudomonas aeruginosa</i> infection in cystic fibrosis. <i>Therapeutic Delivery</i> , 2015, 6, 121-137.	1.2	14
83	Risk Factors for Infection Following Total Joint Arthroplasty in Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , 2013, 7, 119-124.	0.1	84
84	Conjugation of arginine-glycine-aspartic acid peptides to thermoreversible N-isopropylacrylamide polymers. <i>Journal of Polymer Science Part A</i> , 2003, 41, 3989-4000.	2.5	26